Pharmacokinetic models have been developed to assist in extrapolating results from rodent bioassays. However, in numerous circumstances, it is necessary to combine such models with cellular response models to fully define interspecies and dose extrapolations. Interactions between pharmacokinetic target tissue end points (DNA adduct formation) and cellular proliferation in liver and urinary bladder carcinogenesis is illustrated with the results from the ED01 study involving 2-acetylaminofluorene administered to female mice. The interaction of genotoxic and cell proliferative effects are also illustrated in a co-carcinogenesis study with low doses of N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide and high doses of sodium saccharin. The application of such interactions to humans is illustrated for the case of cigarette smoke-induced bladder cancer.
Auerbach O. and Garfinkel L. (1989). Histologic changes in the urinary bladder in relation to cigarette smoking and use of artificial sweeteners. Cancer64: 983-987.
2.
Berenblum I. and Shubik P. (1947). A new quantitative approach to the study of stages of carcinogenesis in the mouse's skin. Br. J. Cancer1: 383-391.
3.
Cohen SM and Ellwein LB (1990). Cell proliferation in carcinogenesis. Science249: 1007-1011.
4.
Cohen SM and Ellwein LB (1990). Proliferative and genotoxic cellular effects in 2-acetylaminofluorene bladder and liver carcinogenesis: Biological modeling of the ED01. Toxicol. Appl. Pharmacol. 104: 79-93.
5.
Cohen SM and Ellwein LB (1990). Cell growth dynamics and DNA alterations in carcinogenesis . In: Scientific Issues in Quantitative Cancer Risk Assessment-Societal Institute of the Mathematical Sciences, SH Moolgavkar (ed). Birkhauser, Boston, pp. 116-135.
6.
Cohen SM and Ellwein LB (1991). Genetic errors, cell proliferation, and carcinogenesis . Cancer Res. 51: 6493-6505.
7.
Cohen SM and Ellwein LB (1992). Risk assessment based on high-dose animal exposure experiments. Chem. Res. Toxicol. 5: 742-748.
8.
Cohen SM, Garland EM, Wehner JM, Johnson LS, and Cano M. (1993). Relationship between bladder changes produced in male rats by sodium saccharin treatment and formation of an insoluble, amorphous material in the urine. Proc. Am. Assoc. Cancer Res . 13: 174.
9.
Cohen SM and Johansson SL (1992). Epidemiology and etiology of bladder cancer. In: Urologic Clinics of North America. W. B. Saunders, Philadelphia, 19: 421-428.
10.
Ellwein LB and Cohen SM (1990). The health risks of saccharin revisited. Crit. Rev. Toxicol. 20: 311-326.
11.
Ellwein LB and Cohen SM (1992). Simulation modeling of carcinogenesis. Toxicol. Appl. Pharmacol. 113: 98-108.
12.
Greenfield RE, Ellwein LB, and Cohen SM (1984). A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. Carcinogenesis5: 437-445.
13.
Kodell RL and Felton RP (1991). Two-stage and Weibull models for carcinogenesis applied to the ED01 discontinued dosing data. Environ. Health Perspect. 92: 155-166.
14.
Moolgavkar SH and Knudson AG Jr (1981). Mutation and cancer: A model for human carcinogenesis. J. Natl. Cancer Inst. 66: 1037-1052.
15.
Murasaki G. and Cohen SM (1983). Co-carcinogenicity of sodium saccharin and N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide for the urinary bladder. Carcinogenesis4: 97-99.
16.
Poirier MC, Fullerton NG, Kinouchi T., Smith BA, and Beland FA (1991). Comparison between DNA adduct formation and tumorigenesis in livers and bladders of mice chronically fed 2-acetylaminofluorene. Carcinogenesis12: 895-900.
17.
Reitz RH, Mendrala AL, Park CN, Andersen ME, and Guengerich FP (1988). Incorporation of in vitro enzyme data into the physiologically-based pharmacokinetic (PB-PK) model for methylene chloride: Implications for risk assessment. Toxicol. Lett. 43: 97-116.
18.
Sakata T., Smith RA, Garland EM, and Cohen SM (1989). Rat urinary bladder epithelial lesions induced by acrolein. J. Environ. Pathol. Toxicol. 9: 159-170.
19.
Staff JA and Mehlman MA (1980). Innovations in cancer risk assessment (ED01 study) . J. Environ. Pathol. Toxicol. 3: 1-246.
20.
Van Ryzin J. (1982). The assessment of low-dose carcinogenicity: Discussion. Biometrics38: 130-139.
21.
Vineis P., Bartsch H., Caporaso N., Harrington AM, Kadlubar FF, Landi MT, Malaveille C., Shields PG, Skipper P., Talaska G., and Tannenbaum SR (1994). Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature (London) 369: 154-156.
